AtriCure (ATRC) Director Sven Wehrwein Exercises Options, Sells Shares

What Happened Sven Wehrwein, a director of AtriCure, exercised 25,000 stock options on July 28, 2026, paying $19.95 per share (total $498,750) and immediately sold 25,000 common shares in an open-market transaction at a weighted average price of $37.84 per share for aggregate proceeds of $946,000. The filing also shows a corresponding derivative conversion/disposition entry for 25,000 shares at $0.00, which reflects the option-to-stock conversion. Net cash proceeds from the sale after the exercise cost were roughly $447,250 before fees and taxes.

Key Details

• Transaction date: July 28, 2026. Form 4 filed July 30, 2026 (appears timely; Form 4s are generally due within 2 business days).
• Exercise: 25,000 options exercised at $19.95/share = $498,750.
• Sale: 25,000 shares sold in open market at weighted avg $37.84/share = $946,000.
• Footnote 1: Sales executed in multiple trades at prices ranging $37.73–$39.04; reported sale price is the weighted average.
• Footnote 2: Options were granted November 11, 2016, with a standard multi-year vesting schedule (25% after one year, then monthly over the next three years).
• Shares owned after the transactions: not specified in the filing.

Context

• This sequence (exercise followed by an immediate sale) is a common cashless-style transaction: the insider exercised vested options and sold the resulting shares the same day to realize value or cover exercise/tax costs. The derivative-disposition entry is the technical record of the options being converted into shares.
• The filing is factual and does not indicate motivation; sales by directors are often routine (liquidity or tax-related) rather than a clear signal about company outlook.